Initial Treatment of Parkinson’s Disease: An Update
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
This is an update to an article published in this journal in 2006, which covered the initial treatment of Parkinson’s disease (PD). In this update, we review new research into symptomatic treatments, potential disease modifying (“neuroprotective”) agents, and evidence-based reviews of current treatment. We discuss the usage of the MAO-B inhibitors, including the controversy surrounding the possible neuroprotective effects of rasagiline. Usage of extended release formulations of pramipexole and ropinirole, as well as the transdermal dopamine agonist rotigotine, are reviewed. Side effects of the dopamine agonists are discussed, including the cardiac side effects of ergot-derived dopamine agonists, and the impulse control disorders associated with the dopamine agonists. The use of zonisamide as an agent for PD tremor is reviewed. We touch on the clinical research into the benefits of exercise in PD, and briefly review some of the current studies for new formulations of levodopa and other medications and treatments with novel mechanisms of action.
- Tarsy D. Initial treatment of Parkinson’s disease. Curr Treat Options Neurol. 2006;8(3):224–35. CrossRef
- Turnbull K, Caslake R, Macleod A, et al. Monoamine oxidase B inhibitors for early Parkinson’s disease. Cochrane Database Syst Rev. 2012;3:CD004898.
- Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61(4):561. CrossRef
- Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361(13):1268. CrossRef
- Ahlskog JE, Uitti RJ. Rasagaline, parkinson neuroprotection, and delayed-start trials. Neurology. 2010;74:1143. CrossRef
- LeWitt PA. MAO-B inhibitor know-how. Back to the pharm. Neurology. 2009;72:1352. CrossRef
- Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagaline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011;10:415. CrossRef
- Hurley D. FDA Committee: rasagiline rejected as ‘Disease Modifying’ for Parkinson Disease. Neurol Today. 2011;11(21);1, 6–7.
- DeMarcaida JA, Schwid SR, White WB, et al. Effects of tyramine administration in Parkinson’s disease patients treated with selective MAO-B inhibitor rasagaline. Mov Disord. 2006;21(10):1716. CrossRef
- Tompson D, Oliver-Willwong R. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson’s disease. Clin Neuropharmacol. 2009;32(3):140–8. CrossRef
- Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68(14):1108–15. CrossRef
- Poewe W, Rascol O, Barone P, Pramipexole ER Studies Group, et al. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology. 2011;77(8):759–66. CrossRef
- Hauser RA, Schapira AH, Rascol O, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson’s disease. Mov Disord. 2010;25(15):2542–9. CrossRef
- Schapira AH, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011;77(8):767–74. CrossRef
- Mizuno Y, Yamamoto M, Kuno S, et al. Efficacy and safety of extended- vs immediate-release pramipexole in Japanese patients with advanced and (L)-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol. 2012;35(4):174–81. CrossRef
- Rascol O, Barone P, Hauser RA, et al. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson’s disease. Mov Disord. 2010;25(14):2326–32. CrossRef
- Schapira AH, Barone P, Hauser RA, et al. Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson’s disease. Eur J Neurol. 2013;20(1):180–7. CrossRef
- Tompson DJ, Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of 2 randomized studies in patients with Parkinson’s disease. Clin Ther. 2007;29(12):2654–66. CrossRef
- Schapira AH, Barone P, Hauser RA, et al. Patient-reported convenience of once-daily vs three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson’s disease. Eur J Neurol. 2013;20(1):50–6. CrossRef
- Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272–6. CrossRef
- Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomized controlled trial. Lancet Neurol. 2007;6(6):513–20. CrossRef
- Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study vs placebo and ropinirole. Mov Disord. 2007;22(16):2398–404. CrossRef
- LeWitt PA, Boroojerdi B, MacMahon D, et al. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007;30:256–65. CrossRef
- Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90–9. CrossRef
- Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589. CrossRef
- Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology. 2006;66(11):1750. CrossRef
- Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969. CrossRef
- Weintraub D, Mamikonyan E, Papay K, et al. Questionnaire for impulsive-compulsive disorders in Parkinson’s Disease Rating Scale. Mov Disord. 2012;27:242. CrossRef
- Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29. CrossRef
- Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356(1):39. CrossRef
- Corvol JC, Anzouan-Kacou JB, Fauveau E, et al. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis. Arch Neurol. 2007;64(12):1721. CrossRef
- Pahwa R, Ellenbogen A, Jankovic J, et al. Efficacy and safety of IPX066, a new carbidopa-levodopa (CDLD) extended-release formulation, in LD-naıve early Parkinson’s disease (APEX-PD trial). Poster session presented at the 15th International Congress of Parkinson’s Disease and Movement Disorders; 2011; Toronto, Canada.
- Hauser RA, Ellenbogen AL, Metman LV, et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson’s disease. Mov Disord. 2011;26(12):2246–52. CrossRef
- Bermejo PE. Zonisamide in patients with essential tremor and Parkinson’s disease. Mov Disord. 2007;22(14):2137–8. CrossRef
- Nakanishi I, Kohmoto J, Miwa H, et al. Effect of zonisamide on resting tremor resistant to antiparkinsonian medication. No to Shinkei. 2003;55(8):685–9.
- Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26 Suppl 3:S42–80. CrossRef
- Parkinson Study Group. Termination of QE3 Study. 2011. Available at http://parkinson-study-group.org/docs/Clinical_Trials_in_Progress/QE3_Final_PSG_Post_May_27_2011_2.pdf. Accessed January 5, 2013.
- Ridgel AL, Vitek JL, Alberts JL. Forced, not voluntary, exercise improves motor function in Parkinson’s disease patients. Neurorehabil Neural Repair. 2009;23:600. CrossRef
- Shulman LM, Katzel LI, Ivey FM, et al. Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease. JAMA Neurol. 2013;70(2):183–90.
- Petzinger GM, Fisher BE, Van Leeuwen J-E, et al. Enhancing neuroplasticity in the basal ganglia: the role of exercise in Parkinson’s disease. Mov Disord. 2010;25 Suppl 1:S141. CrossRef
- Ahlskog JE. Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology. 2011;77:288–94. CrossRef
- Zigmond MJ, Cameron JL, Hoffer BJ, et al. Neurorestoration by physical exercise: moving forward. Parkinsonism Relat Disord. 2012;18 Suppl 1:S147.
- Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson’s disease. N Engl J Med. 2012;366(6):511–9. CrossRef
- Hauser RA. Future treatments for Parkinson’s disease: surfing the PD pipeline. Int J Neurosci. 2011;121 Suppl 2:53. CrossRef
- Initial Treatment of Parkinson’s Disease: An Update
Current Treatment Options in Neurology
Volume 15, Issue 4 , pp 377-384
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Parkinson’s disease
- Initial treatment
- MAO B inhibitors
- Dopamine agonists
- Side effects
- Industry Sectors